Get startedLog in
    Picture of Pharma Mar SA logo

    PHM — Pharma Mar SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapNeutral
    All News

    Brief: Pharma Mar's Phase III Lagoon Trial Of Zepzelca Does Not Meet Primary Overall Survival Endpoint

    Picture of Pharma Mar SA logoPharma Mar SA
    12/06/2026 13:09
    BRIEF-Pharma Mar's Phase III Lagoon Trial Of Zepzelca Does Not Meet Primary Overall Survival Endpoint
    June 12 (Reuters) - Pharma Mar SA PHMR.MC:
    • PHASE III LAGOON TRIAL OF ZEPZELCA DOES NOT MEET PRIMARY OVERALL SURVIVAL ENDPOINT
    • LURBINECTEDIN MONOTHERAPY SHOWS MORE FAVORABLE SAFETY PROFILE THAN CONTROL
    • LAGOON TRIAL RESULTS DO NOT AFFECT FIRST-LINE MAINTENANCE APPROVAL OF LURBINECTEDIN
    Source text: ID:nCNM5C0jrY
    Further company coverage: PHMR.MC

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Pharma Mar SA

    See all news